BIIB Biogen Inc

Price (delayed)

$275.54

Market cap

$42.4B

P/E Ratio

9.11

Dividend/share

N/A

EPS

$30.26

Enterprise value

$48.01B

Sector: Healthcare
Industry: Drug Manufacturers - General

Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, specializing in the discovery, development, and delivery of therapies for the treatment of neurological diseases to patients worldwide. ...

Highlights

The P/E is 39% below the 5-year quarterly average of 15.0
The gross profit is up by 2.2% year-on-year
The company's quick ratio fell by 20% QoQ but it rose by 2.5% YoY
The EPS has contracted by 11% from the previous quarter but it has grown by 7% YoY
The equity has contracted by 23% YoY and by 4.9% from the previous quarter
Biogen's debt has increased by 23% YoY

Key stats

What are the main financial stats of BIIB
Market
Shares outstanding
153.88M
Market cap
$42.4B
Enterprise value
$48.01B
Valuations
Price to earnings (P/E)
9.11
Price to book (P/B)
4.05
Price to sales (P/S)
3.03
EV/EBIT
7.58
EV/EBITDA
7.04
EV/Sales
3.37
Earnings
Revenue
$14.26B
EBIT
$6.34B
EBITDA
$6.82B
Free cash flow
$5.92B
Per share
EPS
$30.26
Free cash flow per share
$37.7
Book value per share
$67.96
Revenue per share
$90.91
TBVPS
$101.05
Balance sheet
Total assets
$24.93B
Total liabilities
$14.19B
Debt
$7.83B
Equity
$10.76B
Working capital
$4.04B
Liquidity
Debt to equity
0.73
Current ratio
2.06
Quick ratio
1.61
Net debt/EBITDA
0.82
Margins
EBITDA margin
47.8%
Gross margin
87.6%
Net margin
35.6%
Operating margin
46.7%
Efficiency
Return on assets
19.6%
Return on equity
42.4%
Return on invested capital
36.9%
Return on capital employed
30%
Return on sales
44.4%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

BIIB stock price

How has the Biogen stock price performed over time
Intraday
2.26%
1 week
-0.11%
1 month
10.71%
1 year
-0.93%
YTD
12.53%
QTD
12.53%

Financial performance

How have Biogen's revenue and profit performed over time
Revenue
$14.26B
Gross profit
$12.5B
Operating income
$6.66B
Net income
$5.08B
Gross margin
87.6%
Net margin
35.6%
Biogen's net income has decreased by 14% QoQ and by 6% YoY
Biogen's net margin has decreased by 13% from the previous quarter and by 6% YoY
BIIB's operating income is down by 10% since the previous quarter
Biogen's operating margin has decreased by 8% from the previous quarter

Growth

What is Biogen's growth rate over time

Valuation

What is Biogen stock price valuation
P/E
9.11
P/B
4.05
P/S
3.03
EV/EBIT
7.58
EV/EBITDA
7.04
EV/Sales
3.37
The P/E is 39% below the 5-year quarterly average of 15.0
The EPS has contracted by 11% from the previous quarter but it has grown by 7% YoY
The equity has contracted by 23% YoY and by 4.9% from the previous quarter
BIIB's price to book (P/B) is 12% lower than its 5-year quarterly average of 4.6
The stock's price to sales (P/S) is 33% less than its 5-year quarterly average of 4.5 and 11% less than its last 4 quarters average of 3.4

Efficiency

How efficient is Biogen business performance
Biogen's return on assets has decreased by 12% QoQ and by 4.4% YoY
The ROIC has contracted by 11% from the previous quarter
The ROS has contracted by 10% from the previous quarter and by 6% YoY
The ROE has contracted by 8% from the previous quarter but it has grown by 6% YoY

Dividends

What is BIIB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BIIB.

Financial health

How did Biogen financials performed over time
The total assets is 76% more than the total liabilities
The company's quick ratio fell by 20% QoQ but it rose by 2.5% YoY
The current ratio has contracted by 16% from the previous quarter but it has grown by 8% YoY
Biogen's debt is 27% less than its equity
The debt to equity has soared by 62% YoY and by 6% from the previous quarter
The equity has contracted by 23% YoY and by 4.9% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.